TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05035849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin and acarbose
Description: One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin and acarbose
Description: One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
Study: NCT04627961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
Study: NCT00824434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element™
Description: Drug eluting coronary stent system
Study: NCT00568334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix (inactivated varicella vaccine)
Description: subcutaneously injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix (inactivated varicella vaccine)
Description: subcutaneously injection
Study: NCT02638376

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)
Description: KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)
Description: KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
Description: The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution.
Study: NCT00601133

Intervention type: BEHAVIORAL
Intervention: Diary
Description: Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
Study: NCT04533828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-04
Description: Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
Study: NCT00414583

Intervention type: OTHER
Intervention: No intervention
Description: Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
Study: NCT02892201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: a constant dose of 200 mg every three weeks, for four cycles.
Study: NCT03595423

Intervention type: PROCEDURE
Intervention: Surgical AVR with bioprosthetic or mechanical prosthesis
Description: Surgical AVR with bioprosthetic or mechanical prosthesis

Intervention type: PROCEDURE
Intervention: Surgical AVR with bioprosthetic or mechanical prosthesis
Description: Surgical AVR with bioprosthetic or mechanical prosthesis
Study: NCT02455999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: SYL1001 eye drops dose C administration for 10 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1001
Description: SYL1001 eye drops dose D administration for 10 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo eye drops administration for 10 consecutive days
Study: NCT04247269

Intervention type: OTHER
Intervention: Enteral Tube Feeding
Description: Enteral tube feeding

Intervention type: OTHER
Intervention: Enteral Tube Feeding
Description: Enteral tube feeding
Study: NCT03415399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1 ARTEMIS™ T cells
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
Study: NCT03384771

Intervention type: BEHAVIORAL
Intervention: MBSR
Description: There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
Study: NCT01944449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein (WPC) at breakfast
Description: The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Protein Sources at breakfast
Description: The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Protein at breakfast
Description: The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
Study: NCT02680197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHF5259 or Placebo administration
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
Study: NCT00336323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Photocoagulation
Description: Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
Study: NCT02206932

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir + Simeprevir
Study: NCT02509988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study nutritional drink
Description: Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard nutritional drink
Description: Standard nutritional drink containing a mix of micronutrients.
Study: NCT03046381

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Tocilizumab 162mg 1x weekly s.c.
Study: NCT03010345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osmed self inflating tissue expanders
Description: Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iliac bone graft
Description: Bone grafting the cleft without the use of osmed self inflating tissue expander
Study: NCT03582345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG/fMRI
Description: All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2.
Study: NCT03272529

Intervention type: OTHER
Intervention: Patient-specific simulated rehearsals
Description: Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.

Intervention type: OTHER
Intervention: Idealized simulated rehearsals
Description: Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.

Intervention type: OTHER
Intervention: Standard simulation
Description: Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
Study: NCT01677949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic cell transplantation
Description: Between Days 28 and 42: infused independent of this study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic cell transplantation
Description: Between Days 28 and 42: infused independent of this study
Study: NCT00336323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
Study: NCT04746365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: ivermectin is anthelmintic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine is antimalarial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard treatments
Study: NCT02927002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive brain stimulation
Study: NCT02419209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose pillules medicated with the Individualised Homeopathic Remedy
Description: Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
Study: NCT02572115

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Akutknappen - used
Description: A caller chooses to bypass the telephone waiting line by pressing the emergency access button

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Akutknappen - not used
Description: A caller chooses NOT to bypass the telephone waiting line.
Study: NCT01069328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 200 mg orally BID interrupted dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 200 mg orally BID interrupted dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg orally BID interrupted dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg orally BID interrupted dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg orally BID interrupted dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Sorafenib 400 mg orally BID interrupted dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 2.5 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10 mg/kg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 intravenously
Study: NCT02867098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb5871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb5871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb5871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb5871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb5871
Study: NCT03065998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opipramol
Description: PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opipramol
Description: PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: PO
Study: NCT01880437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Cohorts 1 and 2: 150 mg orally daily
Study: NCT03352882

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
Study: NCT00005064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT04410549

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Description: To perform OCT in pulmonary artery of patient with COVID-19
Study: NCT04622371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercises
Description: Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercises
Description: Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
Study: NCT01930214

Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).

Intervention type: DEVICE
Intervention: Percutaneous Coronary Intervention
Description: Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
Study: NCT02550912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: vitamin D drops for paediatrics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: glucose syrup with same taste and color to vitamin D3 drops
Study: NCT03589300

Intervention type: DEVICE
Group type: OTHER
Intervention: Persona TM Tibia
Description: Trabecular Metal tibia used in primary cementless total knee arthroplasty